EA2183
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
- NCT04248452 ↗
- Active, not recruiting
- ECOG-ACRIN Cancer Research Group
- Standard
We haven't built an HCP commentary report on EA2183 (oligometastatic HER2-negative esophageal and gastric adenocarcinoma; tests no drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EA2183 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Oligometastatic Esophageal Adenocarcinoma; Oligometastatic Gastric Adenocarcinoma; Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
- Interventions
- Capecitabine; Fluorouracil; Leucovorin; Leucovorin Calcium; Oxaliplatin; Radiation Therapy
- Arms
- Arm A (FOLXFOX) · Experimental
- Arm B (CAPOX) · Experimental
- Arm C (radiation therapy, FOLFOX) · Experimental
- Arm D (FOLFOX) · Active comparator
- Arm E (radiation therapy, CAPOX) · Experimental
- Arm F (CAPOX) · Active comparator
- Enrollment
- 314 (estimated)
- Primary outcomes
- Overall survival
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- May 26, 2020
- Primary completion
- Mar 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04248452 · updated Oct 19, 2026
Publications
linked from the registry- Petrelli F, Ghidini A, Ghidini M, Bukovec R, Trevisan F, Turati L, Indini A, Seghezzi S, Lonati V, Moleri G, Tomasello G, Zaniboni A. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 2021 May 27;10:423. doi: 10.12688/f1000research.52546.4. eCollection 2021. PubMed 35602670